medigraphic.com
ISSN 1560-4381 (Print)

2017, Number 1

<< Back Next >>

Correo Científico Médico 2017; 21 (1)

Analysis of the prostate cancer patients mortality in Holguín province

Sagué LJL, Franco CL, Doimeadios RZ

Language: Spanish
References: 18
Page: 33-43
PDF size: 385.67 Kb.


ABSTRACT

Introduction: prostate cancer has high mortality rate, ranking second in Cuba, surpassed only by tumors of the larynx, trachea and lungs, a similar prevalence is observed in Holguin province.
Objective: to analyze mortality from prostate cancer in the province of Holguin and the factors that can influence in decreasing this mortality.
Method: statistics rate of mortality for prostate cancer from 2001 to 2013 was considered, as well as its incidence taking into account the clinical stage. Statistical Yearbook of Cuba and the data of the Department of Medical Records and Health Statistics in the province (2013) were used. The statistics from 2001 to 2013, mortality from prostate cancer incidence and clinical stage in patients in the province of Holguin were considered. The variables: mortality rate per 100 000 population, incidence, clinical stage according to mortality in patients diagnosed with prostate cancer (2007-2013) in the municipalities, years of potential life lost (YPLL) by age group and mortality trends were analyzed.
Results: the mortality rate in 2013 was 42.8 per 100,000 inhabitants in the province, surpassed only by lung tumors (49.8 per 100,000 inhabitants). The incidence in advanced stages III prevailed in recent years. Gibara, Cueto, Sagua, Frank País and Urbano Noris municipalities had high mortality rates and Moa, Banes, Antilla had lower average rate over the past five years. YPLL in groups of 60-64 years had the higher rate of 6.7 in 2007 being displaced by the 65-69 age group in 2013 with a rate of 6.4.
Conclusions: there is a clear trend towards increased mortality from prostate cancer in Holguin.


REFERENCES

  1. Departamento de registros médicos y estadísticas de salud. Registro Provincial de cáncer. Holguín: Centro Provincial de Higiene y Epidemiología; 2013.

  2. Etzioni R, Gulati R, Tsodikov A, Wever EM, Penson DF, Heijnsdijk EA, et al. The prostate cancer conundrum revisited. Treatment changes and prostate cancer mortality declines. Cancer. 2012 [citado 3 sep 2016]; 118(23):5955–5963. Disponible en: http://onlinelibrary.wiley.com/doi/10.1002/cncr.27594/full

  3. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, and Brawley O, Bray F. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012[citado 8 jun 2016]; 61(6):1079-92. Disponible en: http://www.sciencedirect.com/science/article/pii/S0302283812003053

  4. Sansó Soberats FJ, Alonso Galbán P, Torres Vidal RM. Mortalidad por cáncer en Cuba. Rev Cubana Sal Púb. 2010 [citado 3 sep 2016]; 36(1): 78-94. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-34662010000100009&lng=es

  5. Cuba. Ministerio de Salud Pública. Anuario estadístico de Cuba. La Habana: MINSAP; 2016.

  6. Cuba. Anuario Demográfico de Cuba. Oficina Nacional de Estadísticas. La Habana: ONEI; 2006[citado dic 2015]. Disponible en: http://www.one.cu/PublicacionesDigitales/FichaPublicacion.asp?CodPublicacion=8&CodDireccion=2

  7. Edwards BK, Michelle Noone A, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, et al. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014[citado 3 sep 2016]; 120(9):1290-1314. Disponible en: http://onlinelibrary.wiley.com/doi/10.1002/cncr.28509/full

  8. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012[citado 6 sep 2016]; 62(1):10-29. Disponible en: http://onlinelibrary.wiley.com/doi/10.3322/caac.20138/full

  9. Salas Cabrera R, Rodríguez Expósito F, Sagué Larrea JL, Laurencio Mena A. Factores de Riesgo en el Cáncer de la Próstata. Criterios de expertos. (Método Delphi.). Cien Holguín. 2009 [citado 5 may 2014] ;(4):2-10.Disponible en: http://www.redalyc.org/articulo.oa?id=181518058011

  10. Chowdhury S, Robinson D, Cahill DD, Rodriguez-Vida A, Holmberg L, Møller H. Causes of death in men with prostate cancer: an analysis of 50 000 men from the Thames Cancer Registry. BJU Int. 2013 [citado 26 sep 2016]; 112(2): 182–189. Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/bju.12212/full

  11. Riihimaki M, Thomsen H, Brandt A, Sundquist J, Hemminki K. What do prostate cancer patients die of? Oncologist. 2011[citado 26 sep 2016]; 16(2): 175–181. Disponible en: https://theoncologist.alphamedpress.org/content/16/2/175.full

  12. Millikan RE, Wen S, Pagliaro LC, Brown MA, Moomey B, Do KA et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol. 2008[citado 10 jun 2016]; 26(36): 5936–5942. Disponible en: http://jco.ascopubs.org/content/26/36/5936.full

  13. Lence Anta JJ. Repercusiones éticas de los programas de pesquisaje masivo en el control del cáncer. Rev Cubana Sal Púb. 2007[citado 27 may 2014]; 33(1): Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-34662007000100014&lng=es

  14. Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014[citado 27 may 2015]; 370(10): 932-942.Disponible en: http://www.nejm.org/doi/full/10.1056/NEJMoa1311593

  15. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical Prostatectomy versus Observation for Localized Prostate Cancer. N Engl J Med. 2012[citado 27 may 2015]; 367(3):203-213. Disponible en: http://www.nejm.org/doi/full/10.1056/nejmoa1113162#t=article

  16. Vasdev N, Agarwal S, Rai BP, Soosainathan A, Shaw G, Chang S, et al. Intraoperative Frozen Section of the Prostate Reduces the Risk of Positive Margin Whilst Ensuring Nerve Sparing in Patients with Intermediate and High-Risk Prostate Cancer Undergoing Robotic Radical Prostatectomy: First Reported UK Series. Curr Urol. 2016; 9(2):93-103. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4911535/?report=reader

  17. Furukawa J, Miyake H, Inoue TA, Ogawa T, Tanaka H, Fujisawa M. Oncologic Outcome of Radical Prostatectomy as Monotherapy for Men with High-risk Prostate Cancer. Curr Urol. 2016; 9(2):67-72. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4911533/?report=reader

  18. De Nunzio C, Simone G , Brassetti A, Mastroianni R, Collura D, Muto G ,et al. Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: results from a multicentre prospective study. BMC Cancer. 2016[citado 6 sep 2016]; 16:407. Disponible en: http://bmccancer.biomedcentral.com/articles/10.1186/s12885-016-2442-7




2020     |     www.medigraphic.com